AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia

TOKYO, April 05, 2019 (GLOBE NEWSWIRE) — AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for treating serious diseases, announced today that they have obtained conditional approval (“Approval with Conditions and Time Limit”) from the Japanese Ministry of Health, Labour and Welfare (MHLW) for HGF plasmid to treat patients with critical limb […]

Read more